Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Stanford researchers introduced affordable gene-editing kits ready for the classroom, aiming to make the field more accessible for high school students.

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...

A gene-editing therapy for sickle cell disease ... Crucially foetal haemoglobin is not affected by sickle cell disease, so Crispr acts by dampening down the "switch" that makes the body produce ...

Doudna spoke about all the new opportunities created by the development of the gene-editing tool CRISPR-Cas9. In March last year, Nice rejected Casgevy for people with severe sickle cell disease.

announced Friday a reimbursement agreement with NHS England for eligible sickle cell disease or SCD patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY (exagamglogene autotemcel).

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...